Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1982 1
2006 4
2007 1
2008 3
2009 1
2010 1
2014 1
2015 1
2020 1
2021 3
2022 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Cardiovascular Outcomes in Collegiate Athletes After SARS-CoV-2 Infection: 1-Year Follow-Up From the Outcomes Registry for Cardiac Conditions in Athletes.
Petek BJ, Moulson N, Drezner JA, Harmon KG, Kliethermes SA, Churchill TW, Patel MR, Baggish AL; ORCCA Investigators. Petek BJ, et al. Circulation. 2022 May 31;145(22):1690-1692. doi: 10.1161/CIRCULATIONAHA.121.058272. Epub 2022 May 12. Circulation. 2022. PMID: 35545946 Free article. No abstract available.
Prevalence and clinical implications of persistent or exertional cardiopulmonary symptoms following SARS-CoV-2 infection in 3597 collegiate athletes: a study from the Outcomes Registry for Cardiac Conditions in Athletes (ORCCA).
Petek BJ, Moulson N, Baggish AL, Kliethermes SA, Patel MR, Churchill TW, Harmon KG, Drezner JA; ORCCA Investigators. Petek BJ, et al. Br J Sports Med. 2022 Aug;56(16):913-918. doi: 10.1136/bjsports-2021-104644. Epub 2021 Nov 1. Br J Sports Med. 2022. PMID: 34725052 Free PMC article.
Prevalence of Clinical and Subclinical Myocarditis in Competitive Athletes With Recent SARS-CoV-2 Infection: Results From the Big Ten COVID-19 Cardiac Registry.
Daniels CJ, Rajpal S, Greenshields JT, Rosenthal GL, Chung EH, Terrin M, Jeudy J, Mattson SE, Law IH, Borchers J, Kovacs R, Kovan J, Rifat SF, Albrecht J, Bento AI, Albers L, Bernhardt D, Day C, Hecht S, Hipskind A, Mjaanes J, Olson D, Rooks YL, Somers EC, Tong MS, Wisinski J, Womack J, Esopenko C, Kratochvil CJ, Rink LD; Big Ten COVID-19 Cardiac Registry Investigators. Daniels CJ, et al. Among authors: rink ld. JAMA Cardiol. 2021 Sep 1;6(9):1078-1087. doi: 10.1001/jamacardio.2021.2065. JAMA Cardiol. 2021. PMID: 34042947 Free PMC article.
SARS-CoV-2 Cardiac Involvement in Young Competitive Athletes.
Moulson N, Petek BJ, Drezner JA, Harmon KG, Kliethermes SA, Patel MR, Baggish AL; Outcomes Registry for Cardiac Conditions in Athletes Investigators. Moulson N, et al. Circulation. 2021 Jul 27;144(4):256-266. doi: 10.1161/CIRCULATIONAHA.121.054824. Epub 2021 Apr 17. Circulation. 2021. PMID: 33866822 Free PMC article.
Competitive Sports, the Coronavirus Disease 2019 Pandemic, and Big Ten Athletics.
Big Ten Cardiac Registry Steering Committee; Rink LD, Daniels CJ, Boersma D, Borchers J, Busch J, Kovan J, Kratochvil CJ, Rifat S, Rosenthal G, Chung EH. Big Ten Cardiac Registry Steering Committee, et al. Among authors: rink ld. Circ Cardiovasc Qual Outcomes. 2020 Dec;13(12):e007608. doi: 10.1161/CIRCOUTCOMES.120.007608. Epub 2020 Oct 30. Circ Cardiovasc Qual Outcomes. 2020. PMID: 33125280 Free PMC article. No abstract available.
Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial.
Brinton EA, Kher U, Shah S, Cannon CP, Davidson M, Gotto AM, Ashraf TB, McCrary Sisk C, Dansky H, Mitchel Y, Barter P; DEFINE Investigators. Brinton EA, et al. J Clin Lipidol. 2015 Jan-Feb;9(1):65-71. doi: 10.1016/j.jacl.2014.10.005. Epub 2014 Nov 4. J Clin Lipidol. 2015. PMID: 25670362 Clinical Trial.
Safety of anacetrapib in patients with or at high risk for coronary heart disease.
Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, Stepanavage M, Liu SX, Gibbons P, Ashraf TB, Zafarino J, Mitchel Y, Barter P; Determining the Efficacy and Tolerability Investigators. Cannon CP, et al. N Engl J Med. 2010 Dec 16;363(25):2406-15. doi: 10.1056/NEJMoa1009744. Epub 2010 Nov 17. N Engl J Med. 2010. PMID: 21082868 Free article. Clinical Trial.
19 results